These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Urinary nonesterified cholesterol excretion in adenocarcinoma of the prostate. Belis JA; Cenedella RJ Cancer; 1979 May; 43(5):1840-6. PubMed ID: 445370 [No Abstract] [Full Text] [Related]
6. Assay of thrombopoietin utilizing human sera and urine fractions. McDonald TP Biochem Med; 1975 Jun; 13(2):101-10. PubMed ID: 1191268 [No Abstract] [Full Text] [Related]
7. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma]. de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563 [No Abstract] [Full Text] [Related]
8. Urinary cytology of prostatic duct adenocarcinoma - a clinicopathologic analysis. Sathiyamoorthy S; Ali SZ Acta Cytol; 2013; 57(2):184-8. PubMed ID: 23407018 [TBL] [Abstract][Full Text] [Related]
10. [Cholesterol and urinary tract diseases]. Frick J; Spiteller G Z Urol Nephrol; 1968 Dec; 61(12):833-8. PubMed ID: 4183283 [No Abstract] [Full Text] [Related]
11. Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostatic specific antigen. Rodón N; Trías I; Verdú M; Román R; Domínguez A; Calvo M; Banus JM; Ballesta AM; Maestro ML; Puig X Actas Urol Esp; 2014 Apr; 38(3):150-5. PubMed ID: 24099827 [TBL] [Abstract][Full Text] [Related]
12. [Modification of a biological method of determining thrombocytopoietin]. Putintseva EG Patol Fiziol Eksp Ter; 1979; (6):66-8. PubMed ID: 542338 [No Abstract] [Full Text] [Related]
13. Partial purification and biological properties of thrombopoietin extracted from the urine of aplastic anemia patients. Miyake T; Kawakita M; Enomoto K; Murphy MJ Stem Cells (1981); 1982; 2(3):129-44. PubMed ID: 7163915 [TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical study of urine cytological preparations from secondary prostatic adenocarcinoma involving the urinary bladder. Mai KT; Ahmed I; Robertson SJ; Belanger EC; Veinot JP; Islam S Diagn Cytopathol; 2008 Oct; 36(10):715-20. PubMed ID: 18773445 [TBL] [Abstract][Full Text] [Related]
15. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Jerónimo C; Nomoto S; Caballero OL; Usadel H; Henrique R; Varzim G; Oliveira J; Lopes C; Fliss MS; Sidransky D Oncogene; 2001 Aug; 20(37):5195-8. PubMed ID: 11526508 [TBL] [Abstract][Full Text] [Related]
16. [Urinary excretion of cholesterol in various diseases. (Especially in cancer of the urogenital system)]. Spiteller-Friedmann M; Spiteller G; Spiteller H; Frick J Osterr Z Erforsch Bekampf Krebskr; 1971; 26(1):25-35. PubMed ID: 5171242 [No Abstract] [Full Text] [Related]
18. The treatment of chyluria secondary to advanced carcinoma of the prostate. Cluskey SA; Myatt A; Ferro MA Prostate Cancer Prostatic Dis; 2008; 11(1):102-5. PubMed ID: 17667966 [TBL] [Abstract][Full Text] [Related]
19. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688 [TBL] [Abstract][Full Text] [Related]
20. Demonstrability of thrombopoietic serum activity in patients with disturbed thrombocytopoiesis. Mikita J; Nagy P; Kiss A; Rak K Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):805-9. PubMed ID: 2436994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]